Page updated ·next FDA decision on the calendar·Data as of Nov 5, 2026 9:00 PM ET
Price into the decision (T-120)
Daily close, T-120 (4/21/25) through T+5. Run-up high $21.25 on 10/2/25, low $12.94 on 4/21/25 (T-120 to T-1). FDA decision 10/6/25. Historical price action, not a forecast.
Positioning before the decision
On Sep 22, 2025, 14 days before the decision date, at-the-money options priced a move of ±12.3% through Oct 17, 2025 (the first listed expiry after the decision; ATM implied volatility 59%). The stock closed -0.8% at the first close across the decision and +0.7% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-10-06
DrugZORYVE (roflumilast) Cream 0.05%
IndicationAtopic Dermatitis - ages of 2-5 years old
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
Questions
Was ZORYVE (roflumilast) Cream 0.05% approved by the FDA?
Yes. The FDA approved the application for ZORYVE (roflumilast) Cream 0.05% on October 4, 2025, per the FDA's own record. The company announced it on October 6, 2025. The primary source is linked on this page.
What was ZORYVE (roflumilast) Cream 0.05% under FDA review for?
The application covered Atopic Dermatitis - ages of 2-5 years old. The FDA approved the application on October 6, 2025.
How did ARQT stock react to the FDA decision?
On the decision day ARQT moved -0.8%. That is the recorded reaction to this specific event. Historical measurement, not a prediction, and not investment advice.